Cadernos de Prospecção
2025
Rachel Lais Brandão Viana, Maria Hosana Conceição
Este artigo tem como objetivo realizar uma revisão bibliográfica a respeito da utilização clínica do 3,4-Metilenodioximetanfetamina (MDMA ou Ecstasy) em sessões de psicoterapia do Tratamento do Transtorno de Estresse Pós-Traumático (TEPT). Esse distúrbio é comumente tratado com antidepressivos, que atuam sobre neurotransmissores, além do acompanhamento psicoterapêutico, no entanto, alguns...
Comparative philosophy of religion
2025
Thorsten Botz-Bornstein
1 citation
AbstractMysticism is mostly employed in the context of theistic religions because historically, mysticism aims at a unification with God. It must be clarified if the project of comparative mysticism that this book suggests can be properly carried out when including non-theistic religions. The chapter examines phenomena such as quietism, ekstasis, and contemplation. Further, the relationship...
Addiction and Health
2025
Mohadese Kamali, Hoda Kamali, Arezoo Saberi et al.
Methamphetamine is a common addictive industrial substance. Medicinal plants such as Artemisia absinthium L. with anti-inflammatory, antioxidant, analgesic, neuroprotective, antidepressant, and antipyretic properties may help patients reduce withdrawal syndrome symptoms. Five treatment groups received intraperitoneal (i.p.) injections of 3,4-methylenedioxymethamphetamine (MDMA) and an ethanolic...
Frontiers in Psychiatry
2025
Rocco Miazzi, Clara Cestonaro, Silvia Righetto et al.
This structured review critically examines the psychological and neuropsychological effects of MDMA (3,4-methylenedioxymethamphetamine) use during adolescence, focusing exclusively on human studies. MDMA is a widely consumed psychoactive substance among adolescents, particularly in social and recreational contexts. Drawing on 14 eligible studies identified through a comprehensive literature...
Figshare
2025
Daniel J. Kruger, Gina Mersereau, Ashley Sullivan et al.
preprint
Abstract Background The use of psychedelics is currently increasing in the United States. Awareness of clinical trials investigating the therapeutic applications of psychedelics may result in a record number of people who use psychedelics for the first-time. This study aimed to develop a harm-reduction resource to facilitate safe and successful psychedelic experiences outside of regulated...
Current Addiction Reports
2025
Nina Abukahok, Nicole D. Fitzgerald, Joseph J Palamar
Tusi, also known as "pink cocaine," has emerged across nightlife scenes in Latin America, Europe, Australia, and the United States (US). Tusi is typically a drug mixture containing ketamine and 3,4-methylenedioxymethamphetamine (MDMA). Due to tusi's inconsistent chemical makeup, surveillance and harm reduction efforts have proven difficult for researchers and consumers alike. This review...
Therapeutic Advances in Psychopharmacology
2025
Diana McHerron, Michaela Barber, Rachel Ham et al.
Physical touch is often included as a supportive or therapeutic tool in psychedelic-assisted therapy (PAT), involving instrumental forms of physical contact, supportive touch and somatic techniques. However, participants under the influence of psychedelics have reduced capacity to provide consent, are more suggestible and may experience and interpret therapeutic touch in ways they did not...
PLoS One
2025
Filip Stanicic, Vladimir Zah, Dimitrije Grbic et al.
5 citations
3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) is currently being evaluated for treatment of patients with moderate or higher severity post-traumatic stress disorder (PTSD). To provide a comprehensive summary of investigational MDMA-AT and current treatments for PTSD. A search was conducted in PubMed and Embase (December 20, 2023). Populations included adults with chronic,...
Frontiers in Psychiatry
2025
Julia Marek, Magdalena Domek-Gumprecht, Agata Macionga et al.
PolDrugs is a biennial epidemiological study aimed at analyzing patterns of mostly illicit psychoactive substance use in Poland in the context of psychiatry and harm reduction. This survey was held for the third time, and its results were compared to the last two editions. The survey was conducted as an online survey with 37 closed-ended single-choice questions and 3 multiple-choice questions....
International review of neurobiology
2025
Tijmen Bostoen, Stephan Tap, Joost J. Breeksema et al.
1 citation
Post-Traumatic Stress Disorder (PTSD) is a severe psychiatric condition that develops after exposure to trauma such as combat, natural disasters, or assault. It is characterized by re-experiencing trauma, avoidance, hyperarousal, and negative alterations in cognition and mood. Since its formal inclusion in the Diagnostic and Statistical Manual of Mental Disorders (DSM)-III in 1980, PTSD has...
American Journal of Psychiatry
2025
Aaron Wolfgang, Gregory A. Fonzo, Joshua C. Gray et al.
47 citations
MDMA (i.e., 3,4-methylenedixoymethamphetamine), commonly known as "Ecstasy" or "Molly," has been used since the 1970s both in recreational and therapeutic settings. The Food and Drug Administration (FDA) designated MDMA-Assisted Therapy (MDMA-AT) as a Breakthrough Therapy for posttraumatic stress disorder (PTSD) in 2017, and the FDA is requiring an additional phase 3 trial after rejecting the...
Frontiers in Psychiatry
2025
Dimitri Perivoliotis, Kayla Knopp, Shannon Remick et al.
2 citations
Although effective evidence-based trauma-focused psychotherapies for posttraumatic stress disorder (PTSD) are available, a significant proportion of patients show a suboptimal response or do not complete them. MDMA-assisted therapy (MDMA-AT) for PTSD is a promising intervention currently being evaluated in numerous studies worldwide, including investigation for potential Food and Drug...
Frontiers in Psychiatry
2025
Ella van Beers, Irene de Vries, Caroline Planting et al.
2 citations
Many people with eating disorders report having experienced childhood maltreatment or a traumatic event prior to developing an eating disorder. Although many people with eating disorders have significant traumatic exposure or symptoms of post-traumatic stress disorder, very little research has examined the effects of combined treatments for this group. The purpose of this systematic review was...
Frontiers in Psychiatry
2025
Alexa E Albert, Anthony L. Back
5 citations
Pathological narcissism (PN) is a complex, treatment-resistant disorder characterized by unstable self-esteem that fluctuates between grandiosity and vulnerability, complicating the formation of a stable self-image. With few empirically supported therapies, treatment has traditionally relied on long-term psychoanalytic approaches, but these often face high attrition. Recent research suggests a...
Drug and Alcohol Dependence
2025
James M Zech, David B. Yaden, Grant Jones
9 citations
Cannabis Use Disorder (CUD) is an increasingly prevalent disorder affecting millions of Americans each year. Psychedelic compounds have recently been investigated for their therapeutic potential in treating substance use disorders, yet no prior work has examined the relationship between naturalistic use of specific psychedelic compounds and rates of disordered cannabis use. Using a nationally...
The American Journal of Bioethics
2025
I. Glenn Cohen, Mason Marks
22 citations
Research on psychedelic medicines is experiencing a revival. Some clinicians, scientists, and ethicists believe that psychedelics are so different from other treatments that they warrant special consideration in how they are researched, regulated, commercialized, and administered. Others argue that psychedelic medicines show clinical potential, but they should be treated like other medical...
Frontiers in Psychiatry
2025
Peter Gasser, Matthias E. Liechti, Friederike Holze
2 citations
A 64-year-old male patient who suffered from traumatic life experiences and neuropathic pain after oncological chemotherapy was treated with medium to high doses of lysergic acid diethylamide (LSD) and high doses and microdoses of methylenedioxymethamphetamine (MDMA). At the beginning of treatment, the patient did not experience any acute subjective effects of LSD at a dose of 200 µg. After...
Acta Neuropsychiatrica
2025
Isabel Werle, Marina A. M. Portes, Leandro J Bertoglio
2 citations
Abstract Growing evidence suggests that psychedelic-assisted therapies can alleviate depression, anxiety, posttraumatic stress, and substance use disorder, offering relatively safe profiles, enhanced efficacy, and lasting effects after a few applications. Athletes often experience high levels of stress and pressure, making them susceptible to these psychiatric conditions. However, the effects...